Why Plan B Matters
This article was originally published in RPM Report
Executive Summary
While Barr's attempt to switch the emergency contraceptive Plan B to over-the-counter status is immaterial to the company, the rest of the drug industry can't afford to ignore the controversy, which could jeopardize the renewal of crucial legislation that supports fast and predictable reviews of all new drugs. Moreover, FDA may be reopening old controversies, like whether third parties can force an OTC switch against a brand company's wishes.
You may also be interested in...
Plan C? The Plan B Decision and Calls for a Third Class of Drugs
HHS Secretary Sebelius’ decision to overturn FDA’s approval of Plan B for widespread over-the-counter use was disappointing to many drug reviewers inside the agency. But FDA’s Office of New Drugs Director John Jenkins says the move should be used to reopen the debate over whether to create a third class of drugs. And Plan B, he says, might be a perfect place to start.
Plan C? The Plan B Decision and Calls for a Third Class of Drugs
HHS Secretary Sebelius’ decision to overturn FDA’s approval of Plan B for widespread over-the-counter use was disappointing to many drug reviewers inside the agency. But FDA’s Office of New Drugs Director John Jenkins says the move should be used to reopen the debate over whether to create a third class of drugs. And Plan B, he says, might be a perfect place to start.
Why Wait? Investors Can Expect a More Proactive, Aggressive FDA
Comments made by former FDA offi cials and incoming leadership describe a scenario of nearcrisis and rock-bottom morale. Agency management is taking aggressive action to address those concerns. Investors have zeroed in on the new Commissioner(s).